Stereocontrolled Total Synthesis of (+)-Altohyrtin A/Spongistatin 1 Financial support was provided by the EPSRC (GR/L41646), Cambridge Commonwealth Trust (Scholarship to M.J.C.), EC (Marie Curie Postdoctoral Fellowship to J.L.A.), DFG (Postdoctoral Fellowship to T.T.), NSERC-Canada (Postdoctoral Fellowship to R.M.O.), Churchill College (Research Fellowship to D.J.W.), Kingapos;s College and Sims Fund, Cambridge (Scholarship to D.Y.K.C.). We also thank Merck and AstraZeneca Pharmaceuticals for generous support, and Dr. Anne Butlin (AZ) and Dr. Nick Bampos (Cambridge) for valuable assistance.
作者:Ian Paterson、David Y.-K. Chen、Mark J. Coster、Jose L. Aceña、Jordi Bach、Karl R. Gibson、Linda E. Keown、Renata M. Oballa、Thomas Trieselmann、Debra J. Wallace、Andrew P. Hodgson、Roger D. Norcross
DOI:10.1002/1521-3773(20011105)40:21<4055::aid-anie4055>3.0.co;2-h
日期:2001.11.5
antimitotic macrolide, altohyrtin A/spongistatin 1 shows great promise in cancer chemotherapy but its extreme scarcity in the natural sponges has halted its further preclinical development. A highly stereocontrolled total synthesis, which exploits boron-mediated aldol bond constructions, has been realized to provide, for the first time, a useful amount of synthetic material.
作为一种异常有效的抗有丝分裂大环内酯,altohyrtin A / spongistatin 1在癌症化学疗法中显示出广阔的前景,但其天然海绵中的极度稀缺性阻止了其进一步的临床前开发。已经实现了利用硼介导的羟醛键结构的高度立体控制的全合成,首次提供了有用量的合成材料。